{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T23:15:17Z","timestamp":1787354117620,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Dalian Medical Science Research Program","award":["2312016"],"award-info":[{"award-number":["2312016"]}]},{"name":"Liaoning Province talent plan project","award":["YXMJ-JC-04"],"award-info":[{"award-number":["YXMJ-JC-04"]}]},{"name":"Innovative Teams Project in Key Areas of Dalian","award":["2021RT01"],"award-info":[{"award-number":["2021RT01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06307-6","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:47:09Z","timestamp":1757764029000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["FBXW11 inhibits tumorigenesis by ubiquitinating YB1 in hepatocarcinoma"],"prefix":"10.1007","volume":"151","author":[{"given":"Wuguang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"6307_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110073","volume":"85","author":"A Alkrekshi","year":"2021","unstructured":"Alkrekshi A et al (2021) A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistance. Cell Signal 85:110073","journal-title":"Cell Signal"},{"key":"6307_CR2","unstructured":"Almeida JL, Korch CT (2004) Authentication of human and mouse cell lines by short tandem repeat (STR) DNA genotype analysis. In: Markossian S et al (eds) Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences: Bethesda (MD)"},{"issue":"4","key":"6307_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nm0497-447","volume":"3","author":"RC Bargou","year":"1997","unstructured":"Bargou RC et al (1997) Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 3(4):447\u2013450","journal-title":"Nat Med"},{"issue":"10","key":"6307_CR4","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/sj.onc.1205311","volume":"21","author":"N Bhatia","year":"2002","unstructured":"Bhatia N et al (2002) Mouse homologue of HOS (mHOS) is overexpressed in skin tumors and implicated in constitutive activation of NF-kappaB. Oncogene 21(10):1501\u20131509","journal-title":"Oncogene"},{"issue":"7","key":"6307_CR5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.intimp.2010.12.024","volume":"11","author":"T Chan","year":"2011","unstructured":"Chan T, Wiltrout RH, Weiss JM (2011) Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol 11(7):879\u2013889","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"6307_CR6","first-page":"1131","volume":"10","author":"H Chang","year":"2018","unstructured":"Chang H et al (2018) MiR-182 promotes cell proliferation by suppressing FBXW7 and FBXW11 in non-small cell lung cancer. Am J Transl Res 10(4):1131\u20131142","journal-title":"Am J Transl Res"},{"issue":"7","key":"6307_CR7","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1182\/blood-2007-05-089151","volume":"111","author":"M Chatterjee","year":"2008","unstructured":"Chatterjee M et al (2008) The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 111(7):3714\u20133722","journal-title":"Blood"},{"issue":"8","key":"6307_CR8","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41556-019-0361-y","volume":"21","author":"X Chen","year":"2019","unstructured":"Chen X et al (2019) 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mrnas. Nat Cell Biol 21(8):978\u2013990","journal-title":"Nat Cell Biol"},{"key":"6307_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/genes12101551","author":"A Delicato","year":"2021","unstructured":"Delicato A et al (2021) YB-1 oncoprotein controls PI3K\/Akt pathway by reducing Pten protein level. Genes. https:\/\/doi.org\/10.3390\/genes12101551","journal-title":"Genes"},{"issue":"1","key":"6307_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.14218\/JCTH.2021.00179","volume":"10","author":"ZJ Deng","year":"2022","unstructured":"Deng ZJ et al (2022) Treatments of hepatocellular carcinoma with portal vein tumor thrombus: current status and controversy. J Clin Transl Hepatol 10(1):147\u2013158","journal-title":"J Clin Transl Hepatol"},{"issue":"5","key":"6307_CR11","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/hep.32740","volume":"77","author":"R Donne","year":"2023","unstructured":"Donne R, Lujambio A (2023) The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology 77(5):1773\u20131796","journal-title":"Hepatology"},{"key":"6307_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2407-9-33","volume":"9","author":"F Farinati","year":"2009","unstructured":"Farinati F et al (2009) Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer 9:33","journal-title":"BMC Cancer"},{"issue":"10","key":"6307_CR13","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1200\/JCO.2006.07.8626","volume":"25","author":"D Faury","year":"2007","unstructured":"Faury D et al (2007) Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 25(10):1196\u20131208","journal-title":"J Clin Oncol"},{"issue":"5","key":"6307_CR14","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359\u2013E386","journal-title":"Int J Cancer"},{"issue":"10127","key":"6307_CR15","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391(10127):1301\u20131314","journal-title":"Lancet"},{"issue":"11","key":"6307_CR16","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1038\/sj.onc.1207389","volume":"23","author":"SY Fuchs","year":"2004","unstructured":"Fuchs SY, Spiegelman VS, Kumar KG (2004) The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 23(11):2028\u20132036","journal-title":"Oncogene"},{"issue":"3","key":"6307_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/pros.20023","volume":"59","author":"P Gim\u00e9nez-Bonaf\u00e9","year":"2004","unstructured":"Gim\u00e9nez-Bonaf\u00e9 P et al (2004) YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 59(3):337\u2013349","journal-title":"Prostate"},{"key":"6307_CR18","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1186\/1471-2407-14-970","volume":"14","author":"CP Goswami","year":"2014","unstructured":"Goswami CP, Nakshatri H (2014) PROGgeneV2: enhancements on the existing database. BMC Cancer 14:970","journal-title":"BMC Cancer"},{"key":"6307_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111407","volume":"127","author":"Y Guo","year":"2024","unstructured":"Guo Y et al (2024) Pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1. Int Immunopharmacol 127:111407","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"6307_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.bbrc.2015.01.114","volume":"458","author":"B Ha","year":"2015","unstructured":"Ha B et al (2015) YB-1 overexpression promotes a TGF-\u03b21-induced epithelial-mesenchymal transition via Akt activation. Biochem Biophys Res Commun 458(2):347\u2013351","journal-title":"Biochem Biophys Res Commun"},{"issue":"7237","key":"6307_CR21","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nature07960","volume":"458","author":"D Hoeller","year":"2009","unstructured":"Hoeller D, Dikic I (2009) Targeting the ubiquitin system in cancer therapy. Nature 458(7237):438\u2013444","journal-title":"Nature"},{"issue":"11","key":"6307_CR22","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U","volume":"85","author":"T Kamura","year":"1999","unstructured":"Kamura T et al (1999) Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 85(11):2450\u20132454","journal-title":"Cancer"},{"key":"6307_CR23","doi-asserted-by":"publisher","first-page":"634559","DOI":"10.3389\/fimmu.2021.634559","volume":"12","author":"Q Li","year":"2021","unstructured":"Li Q et al (2021) Case report: clinical responses to Tislelizumab as a first-line therapy for primary hepatocellular carcinoma with B-cell indolent lymphoma. Front Immunol 12:634559","journal-title":"Front Immunol"},{"issue":"7","key":"6307_CR24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/cac2.12164","volume":"41","author":"X Liu","year":"2021","unstructured":"Liu X et al (2021) YB1 regulates miR-205\/200b-ZEB1 axis by inhibiting MicroRNA maturation in hepatocellular carcinoma. Cancer Commun 41(7):576\u2013595","journal-title":"Cancer Commun"},{"issue":"1","key":"6307_CR25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12943-024-02046-3","volume":"23","author":"F Liu","year":"2024","unstructured":"Liu F et al (2024) Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches. Mol Cancer 23(1):148","journal-title":"Mol Cancer"},{"issue":"28","key":"6307_CR26","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.3748\/wjg.v27.i28.4667","volume":"27","author":"T Liu","year":"2021","unstructured":"Liu T et al (2021) Y-box binding protein 1 augments Sorafenib resistance via the PI3K\/Akt signaling pathway in hepatocellular carcinoma. World J Gastroenterol 27(28):4667\u20134686","journal-title":"World J Gastroenterol"},{"issue":"1","key":"6307_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s13402-020-00556-y","volume":"44","author":"L Lou","year":"2021","unstructured":"Lou L et al (2021) Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP). Cell Oncol (Dordr) 44(1):109\u2013133","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"6307_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4049\/jimmunol.1900125","volume":"203","author":"Y Luo","year":"2019","unstructured":"Luo Y et al (2019) CUL7 E3 ubiquitin ligase mediates the degradation of activation-induced cytidine deaminase and regulates the Ig class switch recombination in B lymphocytes. J Immunol 203(1):269\u2013281","journal-title":"J Immunol"},{"issue":"9","key":"6307_CR29","first-page":"2273","volume":"4","author":"Y Oda","year":"1998","unstructured":"Oda Y et al (1998) Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 4(9):2273\u20132277","journal-title":"Clin Cancer Res"},{"key":"6307_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.938557","volume":"12","author":"Z Pu","year":"2022","unstructured":"Pu Z et al (2022) Editorial: the role of tumor microenvironment in primary liver cancer therapeutic resistance. Front Oncol 12:938557","journal-title":"Front Oncol"},{"issue":"4","key":"6307_CR31","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.bbrc.2013.04.025","volume":"434","author":"U Savita","year":"2013","unstructured":"Savita U, Karunagaran D (2013) Microrna-106b-25 cluster targets \u03b2-TRCP2, increases the expression of snail and enhances cell migration and invasion in H1299 (non small cell lung cancer) cells. Biochem Biophys Res Commun 434(4):841\u2013847","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"6307_CR32","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1002\/ijc.22512","volume":"120","author":"B Schittek","year":"2007","unstructured":"Schittek B et al (2007) The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer 120(10):2110\u20132118","journal-title":"Int J Cancer"},{"issue":"10","key":"6307_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41389-020-00276-w","volume":"9","author":"L Shi","year":"2020","unstructured":"Shi L et al (2020) The functional analysis of Cullin 7 E3 ubiquitin ligases in cancer. Oncogenesis 9(10):98","journal-title":"Oncogenesis"},{"issue":"10","key":"6307_CR34","first-page":"3151","volume":"7","author":"K Shibahara","year":"2001","unstructured":"Shibahara K et al (2001) Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 7(10):3151\u20133155","journal-title":"Clin Cancer Res"},{"issue":"6","key":"6307_CR35","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<732::AID-IJC6>3.0.CO;2-#","volume":"83","author":"K Shibao","year":"1999","unstructured":"Shibao K et al (1999) Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. Int J Cancer 83(6):732\u2013737","journal-title":"Int J Cancer"},{"key":"6307_CR36","doi-asserted-by":"publisher","first-page":"1265959","DOI":"10.3389\/fimmu.2023.1265959","volume":"14","author":"K Su","year":"2023","unstructured":"Su K et al (2023) Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (\u2265 5 cm): a multicenter experience over a ten-year period. Front Immunol 14:1265959","journal-title":"Front Immunol"},{"key":"6307_CR37","doi-asserted-by":"publisher","first-page":"1433540","DOI":"10.3389\/fphar.2024.1433540","volume":"15","author":"L Su","year":"2024","unstructured":"Su L et al (2024) Exploiting gender-based biomarkers and drug targets: advancing personalized therapeutic strategies in hepatocellular carcinoma. Front Pharmacol 15:1433540","journal-title":"Front Pharmacol"},{"issue":"1","key":"6307_CR38","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-020-01262-x","volume":"19","author":"T Sun","year":"2020","unstructured":"Sun T, Liu Z, Yang Q (2020) The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer 19(1):146","journal-title":"Mol Cancer"},{"issue":"3","key":"6307_CR39","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"6307_CR40","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.7150\/jca.96744","volume":"15","author":"J Tang","year":"2024","unstructured":"Tang J et al (2024) Causal relationship between immune cells and hepatocellular carcinoma: a Mendelian randomisation study. J Cancer 15(13):4219\u20134231","journal-title":"J Cancer"},{"issue":"9","key":"6307_CR41","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.7150\/thno.42735","volume":"10","author":"DS Tekcham","year":"2020","unstructured":"Tekcham DS et al (2020) F-box proteins and cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects. Theranostics 10(9):4150\u20134167","journal-title":"Theranostics"},{"issue":"D1","key":"6307_CR42","doi-asserted-by":"publisher","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","volume":"46","author":"SV Vasaikar","year":"2018","unstructured":"Vasaikar SV et al (2018) Linkedomics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res 46(D1):D956\u2013D963","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"6307_CR43","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s10620-006-9479-4","volume":"52","author":"W Wang","year":"2007","unstructured":"Wang W et al (2007) Elevated expression of autocrine motility factor receptor correlates with overexpression of RhoC and indicates poor prognosis in hepatocellular carcinoma. Dig Dis Sci 52(3):770\u2013775","journal-title":"Dig Dis Sci"},{"issue":"4","key":"6307_CR44","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrc3700","volume":"14","author":"Z Wang","year":"2014","unstructured":"Wang Z et al (2014) Roles of F-box proteins in cancer. Nat Rev Cancer 14(4):233\u2013247","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"6307_CR45","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41419-018-0440-1","volume":"9","author":"L Wang","year":"2018","unstructured":"Wang L et al (2018) Fbxw11 promotes the proliferation of lymphocytic leukemia cells through the concomitant activation of NF-\u03baB and \u03b2-catenin\/TCF signaling pathways. Cell Death Dis 9(4):427","journal-title":"Cell Death Dis"},{"issue":"12","key":"6307_CR46","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/abbs\/gmw105","volume":"48","author":"S Wang","year":"2016","unstructured":"Wang S et al (2016) Microrna-182 promotes pancreatic cancer cell proliferation and migration by targeting \u03b2-TrCP2. Acta Biochim Biophys Sin 48(12):1085\u20131093","journal-title":"Acta Biochim Biophys Sin"},{"issue":"4","key":"6307_CR47","first-page":"290","volume":"4","author":"AP Wolffe","year":"1992","unstructured":"Wolffe AP et al (1992) The Y-box factors: a family of nucleic acid binding proteins conserved from Escherichia coli to man. New Biol 4(4):290\u2013298","journal-title":"New Biol"},{"issue":"6","key":"6307_CR48","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41419-023-05883-0","volume":"14","author":"W Wu","year":"2023","unstructured":"Wu W et al (2023) TOPK promotes the growth of esophageal cancer in vitro and in vivo by enhancing YB1\/eEF1A1 signal pathway. Cell Death Dis 14(6):364","journal-title":"Cell Death Dis"},{"key":"6307_CR49","first-page":"49","volume":"2","author":"J Wu","year":"2007","unstructured":"Wu J et al (2007) YB-1 is a transcription\/translation factor that orchestrates the oncogenome by hardwiring signal transduction to gene expression. Transl Oncogenomics 2:49\u201365","journal-title":"Transl Oncogenomics"},{"issue":"10","key":"6307_CR50","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41419-021-04185-7","volume":"12","author":"J Yao","year":"2021","unstructured":"Yao J et al (2021) FBXW11 contributes to stem-cell-like features and liver metastasis through regulating HIC1-mediated SIRT1 transcription in colorectal cancer. Cell Death Dis 12(10):930","journal-title":"Cell Death Dis"},{"issue":"20","key":"6307_CR51","doi-asserted-by":"publisher","first-page":"7354","DOI":"10.1158\/1078-0432.CCR-05-1027","volume":"11","author":"M Yasen","year":"2005","unstructured":"Yasen M et al (2005) The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin Cancer Res 11(20):7354\u20137361","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6307_CR52","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1038\/s41598-022-07636-z","volume":"12","author":"Y Zhan","year":"2022","unstructured":"Zhan Y et al (2022) YB1 associates with oncogenetic roles and poor prognosis in nasopharyngeal carcinoma. Sci Rep 12(1):3699","journal-title":"Sci Rep"},{"issue":"7","key":"6307_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206169","volume":"10","author":"J Zhang","year":"2023","unstructured":"Zhang J et al (2023) Emerging epigenetic-based nanotechnology for cancer therapy: modulating the tumor microenvironment. Adv Sci 10(7):e2206169","journal-title":"Adv Sci"},{"key":"6307_CR54","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12935-019-1030-8","volume":"19","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Zheng J, Liu L (2019) The long noncoding RNA PCGEM1 promotes cell proliferation, migration and invasion via targeting the miR-182\/FBXW11 axis in cervical cancer. Cancer Cell Int 19:304","journal-title":"Cancer Cell Int"},{"issue":"16","key":"6307_CR55","doi-asserted-by":"publisher","first-page":"6894","DOI":"10.1002\/cam4.2579","volume":"8","author":"H Zheng","year":"2019","unstructured":"Zheng H et al (2019) Elevated expression of G3BP1 associates with YB1 and p-AKT and predicts poor prognosis in nonsmall cell lung cancer patients after surgical resection. Cancer Med 8(16):6894\u20136903","journal-title":"Cancer Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06307-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06307-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06307-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:05:19Z","timestamp":1758791119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06307-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":55,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["6307"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06307-6","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,13]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All human tissue specimens were collected with written informed consent from participants in accordance with the Declaration of Helsinki. The studies involving human participants were reviewed and approved by the Ethics Committee of The Second hospital of Dalian Medical University. All animal experiments were conducted in compliance with the ARRIVE guidelines and approved by the Institutional Animal Care and Use Committee (IACUC) of Wuhan Servicebio Technology Co., Ltd. Tumor burden was strictly monitored and did not exceed 1.5\u00a0cm in diameter at any time. For anesthesia, mice received intraperitoneal injections of ketamine\/xylazine (100\/10\u00a0mg\/kg). Humane endpoints were applied, and euthanasia was performed via CO\u2082 asphyxiation, consistent with the AVMA Guidelines for the Euthanasia of Animals (2020).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For the use of human tissues, all patients provided explicit consent for participation of anonymized data derived from their specimens.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"256"}}